[CHICAGO, USA – May 14^th, 2025] – The veterinary neuromodulation market is projected to grow at a CAGR of 20.5%, reaching USD 2.1 billion by 2031, according to a new 400-page ClearView Market Insights report. Key drivers include:

Request Sample @ https://clearviewmarketinsights.com/report-details/veterinary-neuromodulation-market/

Industry Shifts

1. Regulatory Pressure:

• EU mandates tVNS for swine stress reduction by 2027.
• FDA designates SCS as "Breakthrough Device" for dogs.

• Nexstim’s CaniStim®: 80% of dogs resume activity in 2 weeks (vs. 6 weeks on drugs).
• VetNeuro’s PulseVet®: Reduces racehorse injuries by 40% (Churchill Downs data).

• 65% of pet owners prefer neuromodulation over opioids (AAHA survey).
• "Stress-Free Pork" labels command 20% price premiums (UK Tesco trial).

Executive Quotes

• Dr. Lisa Rhodes, Nexstim CEO:
  "Our SCS devices are ending the opioid era in veterinary medicine."
• Carlos Mendez, VetNeuro CTO:
  "tVNS turns slaughterhouses from stress zones to calm transitions."

Future Projections

• 2027: First at-home tVNS collar for anxious cats (USD 499 MSRP).
• 2030: 30% of chronic pain pets treated with neuromodulation.

For more insights, visit https://clearviewmarketinsights.com/

About ClearView Market Insights Analytics

ClearView Market Insights Analytics is a global leader in industrial technology research, offering actionable insights across more than 100 laser market segments.

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369